Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, Cancer Research UK and Cambridge University Hospitals NHS Foundation Trust (“CUH”), today announce a collaboration to identify and develop microbiome co-therapeutics and biomarkers for cancer patients receiving immune checkpoint inhibitor therapy.
Conferences
BRAF-Mutant Melanoma Field Continues to Move Forward
Efforts are being made to address remaining questions in the realm of BRAF-mutant melanoma, according to Charles L. Sawyers, MD. Areas of interest include determining the effectiveness of adding immunotherapy to targeted therapy and whether intermittent dosing of BRAF/MEK inhibitor combinations might yield more benefit than continuous dosage.
Tumor-infiltrating lymphocytes show ‘remarkable’ results in advanced melanoma
Lifileucel induced high response rates among patients with advanced melanoma whose disease progressed on immune checkpoint and BRAF/MEK inhibitors, according to study results presented during the ASCO20 Virtual Scientific Program.
Dr. Polsky on the Association Between ctDNA and Survival in Melanoma
David Polsky, MD, PhD, the Alfred W. Kopf, MD, Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology Professor in the Department of Pathology, and director of the Pigmented Lesion Service at NYU Langone Health’s Perlmutter Cancer Center, on the association between circulating tumor (ct)DNA and survival in melanoma.